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ABSTRACT 
A20FMDV2 is a peptide derived from the foot-and-mouth disease virus with a high affinity 
and selectivity for the alpha-v beta-6 (Įvȕ6) arginyl-glycinyl-aspartic acid (RGD)-binding 
integrin. It has been shown to be an informative tool ligand in pre-clinical imaging studies 
for selective labelling of the Įvȕ6 integrin in a number of disease models. In a radioligand 
binding assay using a radiolabelled form of the peptide ([
3
H]A20FMDV2), its high affinity 
(KD: 0.22 nmol/l) and selectivity (at least 85-fold) for Įvȕ6 over the other members of the 
RGD integrin family was confirmed. [
3
H]A20FMDV2 Įvȕ6 binding could only be fully 
reversed in the presence of EDTA whereas a partial reversal was observed in the presence of 
excess concentrations of an RGD-mimetic small molecule (SC-68448) or unlabelled 
A20FMDV2. Using flow cytometry on bronchial epithelial cells, the ligand-induced 
internalization of Įvȕ6 by A20FMDV2 and LAP1 was shown to be fast (t1/2: 1.5 and 3.1 
min,  respectively), concentration-dependent (EC50: values 1.1 and 3.6 nmol/l, respectively) 
and was followed by a moderately slow return of integrin to the surface. The resultsof the 
radioligand binding studies suggest that the binding of A20FMDV2 to the RGD binding site 
on Įvȕ6 is required to maintain its engagement with the hypothesised A20FMDV2 synergy 
site on the integrin. In addition, there is evidence from flow cytometric studies that the 
RGD-ligand engagement of Įvȕ6 post-internalization plays a role in delaying recycling of 
the integrin to the cell surface. This mechanism may act as a homeostatic control of 
membrane Įvȕ6 following RGD ligand engagement. 
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INTRODUCTION 
Integrins are heterodimeric, transmembrane glycoprotein receptors that have a primary 
function to act as signalling proteins in mammals [1]. They are composed of an Į and ȕ-
subunit, of which in mammals there are 18 and 8 variants, respectively, that can form up to 
24 heterodimers [2]. The Į and ȕ-subunits are bound in a noncovalent complex and their 
primary role is to act as adhesion receptors. In order to fulfil this role they have the ability to 
signal in both directions across the plasma membrane, termed inside-out signalling [3], 
through binding to extracellular ligands and through cytoplasmic proteins binding to their 
intracellular domains. 
The integrin family is split into sub-families based on a common Į or ȕ-subunit or related 
properties. The arginyl-glycinyl-aspartic acid (RGD) sub-family of integrins share an amino 
acid binding motif (arginine (R), glycine (G) and aspartic acid (D)) in their endogenous 
ligands, with selectivity for these ligands determined by their surrounding amino acid 
sequences [4]. The RGD family of integrins includes the epithelial-restricted integrin alpha-
v beta-6 (Įvȕ6) that was first identified in the early 1990s [5] and which demonstrates a high 
affinity for fibronectin, tenascin, latency associated peptide-1 (LAP1) and LAP3. In the 
epithelia of healthy adults, its expression is very low with the exception of the endometrium 
during the menstrual cycle [5] and diffuse expression associated with subclinical 
inflammation in the lung and kidney [6]. However, Įvȕ6 has been identified as being able to 
activate transforming growth factor-ȕ1 (TGFȕ1) by binding to LAP on the constitutively 
expressed latent TGFȕ1 [7]. Upon tissue injury, inflammation and cancer the expression of 
this integrin is observed to be upregulated significantly. This has been shown in a range of 
diseases and organs that include acute lung injury and idiopathic pulmonary fibrosis (IPF) in 
the lung [8,9], fibrosis of the liver and kidney [10,11] and carcinomas of the breast, lung, 
mouth, skin, colon, stomach and endometrium among others [12]. These observations, 
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combined with additional data showing Įvȕ6 inhibition to have positive outcomes in pre-
clinical models of fibrosis and cancer [9,10,13], make this integrin a potential therapeutic 
target for these diseases where the normal control of TGFȕ activation has become disrupted. 
A20FMDV2 is a 20 amino acid peptide (NAVPNLRGDLQVLAQKVART, fig. 1) derived 
from the foot-and-mouth disease virus (FMDV) with a high affinity and selectivity for the 
Įvȕ6 RGD integrin [14]. It has been shown to be an informative tool ligand in pre-clinical 
imaging studies for selective labelling of the Įvȕ6 integrin in a number of disease models 
[15-17]. Although the high affinity and selectivity of A20FMDV2 has been described 
previously [14], an accurate determination of its association and dissociation binding 
kinetics with Įvȕ6 has not been fully defined and this study addresses this by use of a 
radiolabelled form of the peptide ([
3
H]A20FMDV2) to characterize these properties. In 
addition, while it is well established that A20FMDV2 induces internalization of the Įvȕ6 
integrin [15,16], the kinetics of its return to the cell surface following ligand induced 
internalization is less well described. To further explore this, a flow cytometric assay was 
developed using normal human bronchial epithelial (NHBE) cells to track Įvȕ6 location in a 
primary cell line that also allowed a direct comparison of the effects of A20FMDV2 with 
those of the endogenous Įvȕ6 ligand latency associated peptide-1 (LAP1). 
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MATERIALS AND METHODS 
Materials 
SC-68448 [18] and cilengitide [19] (fig. 1) were synthesised by the Fibrosis Discovery 
Performance Unit Medicinal Chemistry group at GSK Medicines Research Centre 
(Stevenage, UK). Full length LAPȕ1 (fLAP1) (fig. 1) was purchased from Sigma-Aldrich 
Co. Ltd. (Gillingham, UK). Truncated LAPȕ1 (tLAP1) and the Įvȕ6 selective peptide 
NAVPNLRGDLQVLAQKVART (A20FMDV2 derived from the foot-and-mouth disease 
virus were synthesized by Cambridge Research Biochemicals (Cleveland, UK) (fig. 1). 
A20FMDV2 was radiolabelled with [
3
H] by Quotient Bioresearch (Radiochemicals) Ltd. 
(Cardiff, UK) and had a specific activity of 20 Ci/mmol (incorporation of [
3
H] determined 
by mass spectrometry and nuclear magnetic resonance). All other chemicals and reagents 
were purchased from Sigma-Aldrich Co. Ltd. (Gillingham, UK) unless otherwise stated. 
NHBE cells, growth medium and supplements were purchased from Lonza (Lonza Group 
Ltd, Basel, Switzerland). All other cell culture media and reagents were obtained from 
Invitrogen (Invitrogen Ltd., Paisley, UK). All tissue culture flasks and plates were purchased 
from Greiner Bio-One (Firckenhausen, Germany) unless otherwise stated. All antibodies 
used were commercially available and obtained from R&D Systems (Minneapolis, MN, 
USA) unless otherwise stated and at a stock concentration of 10 µg/ml. These included for 
flow cytometry phycoerythrin (PE) conjugated mouse IgG2B isotype control (IgG2B-PE) 
and PE-conjugated mouse monoclonal non-function blocking, anti-human integrin beta-6 
(hȕ6-PE) and for high content screening (HCS) mouse IgG2B isotype control (IgG2B-HCS), 
mouse monoclonal anti-human integrin beta-6 (hȕ6-HCS) and Alexa Fluor 488 goat IgG 
anti-mouse Invitrogen (Invitrogen Ltd., Paisley, UK). Cellular assays and radioligand 
binding assays were completed with a final dimethyl sulphoxide (DMSO) concentration of 
0.1% and 1% respectively, unless otherwise stated. Purified soluble protein preparations for 
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the human integrin proteins Įvȕ1, Įvȕ3, Įvȕ5, Įvȕ6, Įvȕ8, Į5ȕ1, Į8ȕ1 and ĮIIbȕ3 were all 
purchased from R&D Systems Inc. (Minneapolis, MN, USA) except for Į8ȕ1 that was 
generated by the Biological Sciences department at GSK Medicines Research Centre 
(Stevenage, UK). 
NHBE Cell Culture 
Frozen aliquots of NHBE cells were placed into culture as a monolayer adhered in type I 
collagen coated T75 cm
3
 or T175 cm
3
 tissue culture flasks using aseptic techniques. Cells 
were maintained in NHBE cell medium (bronchial epithelial growth medium (BEGM™) 
containing 0.6 mmol/l MgCl2) supplemented with BEGM™ Clonetics™ SingleQuots 
(containing bovine pituitary extract, insulin, hydrocortisone, GA-1000 (consisting of 30 
mg/ml gentamicin and 15 µg/ml amphotericin), retinoic acid, transferrin, triiodothyronine, 
epinephrine and human epidermal growth factor)) in 95%:5% air:CO2 at 37ºC and were 
harvested when ~80% confluent using Accutase®. Cells were then re-suspended in PBS, 
centrifuged at 300 g for 5 min prior to re-suspension in either NHBE cell medium or flow 
cytometry buffer (RPMI 1640 (without L-glutamine and phenol red) containing 10 mmol/l 
HEPES, 1% w/v bovine serum albumin (BSA) and 2 mmol/l MgCl2). Cells were then 
counted on a NucleoCounter NC-3000 (ChemoMetec, Allerød, Denmark) and re-suspended 
to the required cell density (as detailed beow). 
Radioligand Binding Studies 
All radioligand binding experiments were performed in 96-deep well plates at 37ºC in 
binding buffer (25 mmol/l 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 
100 mmol/l NaCl, 2 mmol/l MgCl2 (unless otherwise stated) and 1 mmol/l 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) at pH 7.4 (NaOH)). 
Radioligand binding studies were completed with recombinant soluble integrin proteins in a 
total volume of 0.5 ml consisting of 50 µl/well of either unlabelled compound at varying 
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concentrations or vehicle (1% DMSO), 50 µl of [
3
H]A20FMDV2 and 400 µl/well of 
purified integrin (0.3 or 2 nmol/l for Įvȕ6 and 2 nmol/l for Įvȕ1, Įvȕ3, Įvȕ5, Įvȕ8, Į5ȕ1, 
Į8ȕ1 and ĮIIbȕ3).  
Non-specific binding (NSB) was determined with either 10 µmol/l SC-68448 (pan-Įv small 
molecule RGD-mimetic [18]), 1 µmol/l A20FMDV2 or 10 mmol/l EDTA (chelating agent). 
Specific binding was measured by subtracting the NSB from the total radioligand binding in 
the presence of vehicle (1% DMSO). Plates were incubated with gentle agitation for the time 
periods indicated and binding terminated by rapid vacuum filtration through a 48-well 
Brandel harvester (Brandel Inc. Gaithersburg, MD, USA) onto GF/C filter papers pre-soaked 
in 0.3% v/v poly-ethylenimine. Samples were washed rapidly three times with ice cold 
distilled water (dH2O) and filters transferred into liquid scintillation (LS) vials containing 4 
ml LS fluid (Ultima-Flo M, PerkinElmer LAS UK Ltd., Beaconsfield, UK). The amount 
of radioligand bound to integrin protein was measured by LS spectroscopy using a TriCarb 
2900 TR LS counter (PerkinElmer LAS UK Ltd., Beaconsfield, UK). 
Association, dissociation and saturation binding studies were performed with 
[
3
H]A20FMDV2 to determine radioligand binding kinetics at the human Įvȕ6 integrin 
(association rate constant (kon), dissociation rate constant (koff) and equilibrium dissociation 
constant (KD) were calculated as described under section Data analysis). For association 
binding studies, Įvȕ6 integrin was incubated with varying concentrations of 
[
3
H]A20FMDV2 (~0.3 to 2 nmol/l) for varying times up to 2 h prior to filtration. For 
dissociation binding Įvȕ6 integrin was pre-incubated for 1 h with a fixed concentration of 
[
3
H]A20FMDV2 (~2 nmol/l) before dissociation was initiated by either the addition of an 
excess of unlabelled compound or 10 mmol/l EDTA before incubation for varying times up 
to 24 h prior to filtration. For saturation binding Įvȕ6 integrin protein was incubated with a 
range of concentrations of [
3
H]A20FMDV2 (~0.01 to 6 nmol/l) for 6 h prior to filtration. For 
 8
RGD integrin selectivity studies 20 nmol/l [
3
H]A20FMDV2 was incubated for 2 h with 
purified integrin protein prior to filtration. To demonstrate the divalent cation dependency of 
integrin binding the specific binding window of a saturating concentration of 
[
3
H]A20FMDV2 (~1 nmol/l) was measured against Įvȕ6 in the absence and presence of a 
range of concentrations of Ca
2+
, Mg
2+
 and Mn
2+
 following a 4 h incubation. 
In order to determine the affinity of integrin ligands for the Įvȕ6 integrin, competition 
binding displacement studies were completed where Įvȕ6 integrin was incubated with a 
fixed concentration of [
3
H]A20FMDV2 (~2 nmol/l) and increasing concentrations of 
unlabelled test ligand for 6 h prior to filtration.  
Flow Cytometric Analysis of Įvȕ6 Expression 
All flow cytometry assays were performed in 96 well polypropylene microplates with 
NHBE cells suspended in flow cytometry buffer (45 µl/well with 70,000 cells/well) in the 
presence of 5 µl/well compound or vehicle (0.1% DMSO). Where stated, cells were 
permeabilised by incubating with 0.2 % w/v saponin for 5 min at ambient temperature (20-
22ºC) prior to compound/vehicle addition. Inhibition of clathrin or lipid raft mediated 
endocytosis was investigated by pre-incubating NHBE cells with either 2 µg/ml 
chlorpromazine or 10 µg/ml filipin [20] respectively, for 5 min prior to addition of 
compound or vehicle (0.1% DMSO). Experiments were stopped by addition of 10 µl/well 
IgG2B-PE or hȕ6-PE and transferring plates to 4oC for 1 h. Plates were then washed twice 
by centrifuging at 300 g for 5 min, removing supernatant and adding flow cytometry buffer 
(150 µl/well). After the second wash cells were resuspended in flow cytometry buffer (200 
µl/well) and cell suspensions transferred into a 96 well round bottom polypropylene plate 
(Corning Inc. Life Sciences, Tewksbury, MA, USA). Cell samples were then acquired on a 
fluorescence activated cell sorting (FACS) Canto II (BD Biosciences, San Jose, CA, USA) 
using a high throughput sampler system and BD FACS Diva version 6.1.3 software.  Cells 
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were identified by their forward and side-scatter characteristics and the mean fluorescence 
intensity of antibody conjugated cells measured. The fluorescence was quantified on at least 
5,000 cells and following acquisition all data was exported as flow cytometry standard 
format 3.0 files with raw data values captured as mean fluorescence intensity (MFI). 
Fluorescence-activated cell analyses histograms were plotted using FlowJo software (Tree 
Star Inc. Ashland, OR, USA). 
For internalization concentration-response curves NHBE cells were added to 96 well 
polypropylene microplates containing 5 µl/well compound at varying concentrations or 
vehicle (0.1% DMSO). Plates were incubated for 2 h in 95%:5% air:CO2 at 37ºC prior to 
addition of 10 µl IgG2B-PE or hȕ6-PE antibody. For determining the rate of ligand-induced 
Įvȕ6 internalization NHBE cells were added to 96 well polypropylene microplates 
containing 5 µl/well compound (at a concentration that caused maximal internalization) or 
vehicle (0.1% DMSO). Plates were incubated in 95%:5% air:CO2 at 37°C for varying times 
up to 1 h and then transferred immediately on to ice to stop any further internalization. 10 
µl/well IgG2B-PE or hȕ6-PE antibody were then added to plates. For determining the rate of 
Įvȕ6 return to the cell surface (reversal of ligand-induced Įvȕ6 internalization), NHBE cells 
were added to 96 well polypropylene microplates containing 5 µl/well compound (at a 
concentration that caused maximal internalization) or vehicle (0.1% DMSO). Plates were 
incubated in in 95%:5% air:CO2 at 37°C for 1 h then centrifuged at 500 g for 5 min, 
supernatant removed and cell pellets re-suspended in PBS (150 µl/well). This process was 
repeated prior to re-suspension of cells in cell medium (150 µl/well) and incubation for 
varying times up to 48 h. Plates were then transferred on to ice and 10 µl/well IgG2B-PE or 
hȕ6-PE antibody added. All samples were then processed and read on the FACS Canto II as 
detailed above.  
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Data Analysis 
Analysis of all experiments was completed using GraphPad Prism 5.0 (GraphPad Software, 
San Diego, CA, USA). In order to allow the results between binding experiments to be 
averaged, where appropriate, disintegrations per minute (DPM) values were normalized to 
give the amount (in femtomoles as calculated by the methods preiously described [21]) of 
radioligand bound per amount (ng) of purified protein (fmol/ng).  
Specific binding data from association binding experiments were fitted globally to the 
association kinetic model (Equation 1, where Kob is the observed rate constant of the 
association reaction, kon is the association rate constant in units of inverse molar time inverse 
time (M
-1
.min
-1
) and koff is the dissociation rate constant in inverse units of time (min
-1
)). 
From Equation 1 Kob values were subsequently used to calculate association half-life (t1/2) 
values at fixed radioligand concentrations using the equation t1/2 = 0.693/Kob. 
 
To calculate the percentage of radioligand bound in dissociation binding studies at each time 
point, Equation 2 was used (where TB is total binding of radioligand determined in the 
presence of vehicle (1% DMSO), Binding is the level of binding observed in test well and 
NSB is non-specific binding determined in the presence of either excess unlabelled ligand or 
EDTA, all measured at the same time point in DPM).  
 
Dissociation binding data were fitted to a one-phase dissociation model (Equation 3, where 
koff is the dissociation rate constant in inverse units of time (min
-1
) and NSBt= is non-
specific binding determined at infinite time). 
 
(1) 
(2) 
(3) 
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From Equation 3 koff values were subsequently used to calculate dissociation half-life (t1/2) 
values using the equation t1/2 = 0.693/koff. Specific binding data from saturation experiments 
were fitted to a one affinity site model (Equation 4, where nH is the Hill coefficient and K is 
the mid-point of the binding isotherm) where appropriate to determine KD. For visualisation 
only, specific binding data from saturation experiments were also analysed via Scatchard 
transformation [22] using the method previously described [21]. 
  
All concentration response curves and competition binding displacement curves were fitted 
using non-linear regression analysis (four-parameter logistic equation with variable slope 
[23]) with EC50 or IC50 values calculated from the fits. 
  
To calculate the percentage inhibition of radioligand binding Equation 5 was used (where 
TB is total binding of radioligand (DPM) determined in the presence of vehicle (1% 
DMSO), Binding is the level of binding observed in DPM at a particular concentration of 
unlabelled integrin ligand and NSB is non-specific binding determined in the presence of 10 
µmol/l SC-68448. IC50 values generated from competition binding curves against 
[
3
H]A20FMDV2 ([
3
H]A20FMDV2 saturation binding curve nH = 1) were converted to 
equilibrium dissociation constant (KI) values using the Cheng-Prusoff equation [24] 
(Equation 6, where L
*
 is the radioligand concentration).  
 
(4) 
(6) 
(5) 
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Measurement of the ȕ6 integrin subunit via hȕ6-PE binding in flow cytometric assays was 
used as a surrogate for tracking the location of the Įvȕ6 heterodimer and for ligand-induced 
internalization concentration response curves data were expressed as % internalized Įvȕ6 
using Equation 7 (where x represents the MFI of hȕ6-PE staining in the absence of 
compound, y represents the MFI of hȕ6-PE staining in the presence of compound and z 
represents the MFI of isotype control (IgG2B-PE) staining). 
 
For rates of ligand-induced internalization and subsequent recycling of ȕ6, data were 
expressed as % Įvȕ6 surface expression using Equation 8 (where % Įvȕ6 SE is the % Įvȕ6 
surface expression, x represents the MFI of hȕ6-PE staining in the absence of compound, y 
represents the MFI of hȕ6-PE staining in the presence of compound and z represents the 
MFI of isotype control (IgG2B-PE) staining). 
 
The ligand-induced ȕ6 internalization data for compounds were fitted to a one-phase decay 
model (Equation 9, where % Įvȕ6 SE is the % Įvȕ6 surface expression, kin is the 
internalization rate constant in inverse units of time (min
-1
) and % Įvȕ6SEt= is % Įvȕ6 
surface expression determined at infinite time). Internalization half-life (t1/2) values were 
calculated using the equation t1/2 = 0.693/kin. 
 
For statistical analyses, differences of p < 0.05 were considered to be statistically significant. 
For determination of statistical difference between a single data set and a hypothetical value 
a one-sample t-test was carried out. Statistical significance between two data sets was tested 
using a Students unpaired t-test. One-way analysis of variance (ANOVA) was used for 
(7) 
(8) 
(9) 
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comparison of more than two datasets. Unless otherwise indicated, data shown graphically 
and in the text are either mean ± standard deviation (SD) or, where three or more data 
points/individual experiments have been completed, mean ± standard error of the mean 
(SEM). 
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RESULTS 
Characterisation of the binding of [
3
H]A20FMDV2 with the Įvȕ6 integrin 
In kinetic binding studies the association of [
3
H]A20FMDV2 to the Įvȕ6 integrin was 
measured at ~KD and 5 x KD concentrations of radioligand. Global fitting of the association 
kinetic model to specific association binding data resulted in a kon value of 5.7 ± 0.2 x 10
7
 M
-
1
.min
-1 
(mean ± SEM, n=4) (fig. 2a). The dissociation profiles observed for [
3
H]A20FMDV2 
when initiated by 10 µmol/l SC-68448 or 1 µmol/l A20FMDV2 were comparable and only a 
partial dissociation of the radioligand was observed (fig. 2b). However, with 10 mmol/l 
EDTA a single phase dissociation of [
3
H]A20FMDV2 binding from the Įvȕ6 integrin was 
observed with complete dissociation achieved (fig. 2b) with a t1/2 of 2.0 ± 0.5 h (mean ± 
SEM, n=4). Specific binding data from saturation experiments with [
3
H]A20FMDV2 were 
fitted to a one affinity site model (with nH) and analysis resulted in the pKD and nH values 
shown in Table 1. The binding to Įvȕ6 was saturable and high affinity (fig. 2c) with the nH 
not significantly different from unity (one-sample t-test completed on log10 nH vs 0, p > 
0.05) suggesting the binding of [
3
H]A20FMDV2 to Įvȕ6 followed the law of mass action at 
a single site at the range of radioligand concentrations tested in these studies. In addition, no 
specific binding of [
3
H]A20FMDV2 was observed to any of the non-Įvȕ6 RGD integrins 
investigated (fig. 2d) when tested at ~20 nmol/l radioligand (~100 times [
3
H]A20FMDV2s 
Įvȕ6 KD). 
Binding of [
3
H]A20FMDV2 to Įvȕ6 required the presence of divalent cations with Ca2+, 
Mg
2+
 and Mn
2+
 able to support binding (fig. 3a). All enabled maximal binding of 
[
3
H]A20FMDV2 to Įvȕ6 however Mn2+ was able to support this at much lower 
concentrations compared with Mg
2+
 and Ca
2+
. In order to determine the affinity of 
unlabelled RGD-ligands at the Įvȕ6 integrin under equilibrium conditions, competition 
displacement binding curves were measured against [
3
H]A20FMDV2 following a 6 h 
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incubation period. The pKI values determined for a range of unlabelled RGD-ligands are 
summarised in Table 1. All unlabelled ligands inhibited the binding of [
3
H]A20FMDV2 
except the Įvȕ3/5 selective ligand cilengitide (based on the cyclic peptide cyclo(-RGDfV-) 
(19)) when tested up to 1 µmol/l. All ligands that did inhibit binding (except fLAP1 against 
[
3
H]A20FMDV2 due to the inability to test at concentrations above 50 nmol/l) caused 
inhibition of radioligand binding to NSB levels (fig. 3b). The pKI value determined for the 
unlabelled A20FMDV2 was not significantly different to the pKD value determined in 
saturation binding studies with A20FMDV2 (Students unpaired t-test, p > 0.05). 
RGD ligand-induced internalization of Įvȕ6 
To quantitatively measure the surface (membrane) and total (membrane and intracellular 
pools) NHBE cell expression of Įvȕ6, flow cytometric assays were completed using hȕ6-PE 
to measure the ȕ6 subunit as a surrogate for the heterodimer (ȕ6 does not pair with any other 
Į integrin subunit). To validate the use of flow cytometry to measure internalization of Įvȕ6 
the endogenous ligand fLAP1 was tested in the absence and presence of 0.2 % w/v saponin 
to investigate surface and total cell integrin populations respectively. In the absence of 
saponin a significant reduction in surface expression of the ȕ6 subunit was observed in the 
presence of fLAP1 (fig. 4a (panel 2) and fig. 4b) (ANOVA, Bonferroni post-test, p < 0.05) 
with MFI values not significantly different from those in the presence of IgG2B-PE isotype 
control (ANOVA, Bonferroni post-test, p > 0.05). When cells were permeabilised in the 
presence of saponin to allow antibodies intracellular access, there was no significant 
difference observed between hȕ6-PE with and without fLAP1 (ANOVA, Bonferroni post-
test, p > 0.05) (fig. 4a (panel 4) and fig. 4b). In addition, 0.2 % w/v saponin (concentration 
used to permeabilise NHBE cells) did not reduce the affinity of tLAP1 for the Įvȕ6 integrin 
in a radioligand competition binding assay (data not shown). Based on the MFI values for 
hȕ6-PE in permeabilised (total cell staining) and unpermeabilised (membrane staining) 
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NHBE cells in the presence of 0.1 % DMSO, ~36% of Įvȕ6 integrin was present 
intracellularly and ~64% at the cell surface. The internalization observed in the presence of 
fLAP1 was significantly inhibited when NHBE cells were pre-incubated with the clathrin-
coated pits inhibitor chlorpromazine (ANOVA, Bonferroni post-test, p < 0.05) whilst the 
lipid rafts inhibitor filipin had no effect (fig. 5).  
Kinetics of RGD ligand-induced Įvȕ6 internalization 
fLAP1 and A20FMDV2 both caused concentration-dependent ligand-induced Įvȕ6 
internalization following a 2 h incubation with NHBE cells (fig. 6a). The pEC50 values for 
internalization of Įvȕ6 by fLAP1 and A20FMDV2 were 8.45 ± 0.07 and 9.01 ± 0.13 
respectively (mean ± SEM, n=4).To determine the rates of ligand-induced internalization the 
surface expression of Įvȕ6 was measured over time following the addition of a maximal 
concentration of fLAP1 or A20FMDV2, as determined in concentration response studies. 
Both RGD-ligands caused a rapid internalization of Įvȕ6 (fLAP1 t1/2 3.1 ± 0.8 and 
A20FMDV2 t1/2 1.5 ± 0.6 min (mean ± SEM, n=4) with no significant difference observed 
between t1/2 (Students unpaired t-test, p > 0.05)). A maximal loss of 79% and 80% cell 
surface integrin was observed for fLAP, and A20FMDV2 respectively, over the 1 h time 
course studied (fig. 6b). To measure the return of Įvȕ6 to the surface membrane, washout 
studies were completed where a maximal concentration of fLAP1 (60 nM) or A20FMDV2 (1 
µM) was incubated with NHBE cells for 1 h followed by the removal of Įvȕ6 ligand and 
washing of cells in PBS twice. Cells were then incubated for increasing time periods up to 
48 h and surface expression of Įvȕ6 measured at different intervals by flow cytometry. The 
rate of return of Įvȕ6 to the cell surface was moderately slow post-washout of both RGD-
ligands with 58% and 61% of the total integrin returned to the surface at 48 h still 
internalized at 4 h (fig. 6b) for A20FMDV2 and fLAP1. 
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DISCUSSION 
With the FMDV derived peptide A20FMDV2 demonstrating such a high affinity and 
selectivity for Įvȕ6, it has been used to great effect as a tool in the cancer field, especially as 
a radiotracer for in vivo imaging studies investigating Įvȕ6 expression in tumours [14,15]. 
In this study, A20FMDV2 has been used as tool peptide for comparison with the 
endogenous Įvȕ6 ligand LAP1. A number of characteristics of A20FMDV2 demonstrated in 
previously published studies have been confirmed here with the use of a [
3
H] labelled form 
of the peptide. For example, the high affinity and selectivity of A20FMDV2 for the Įvȕ6 
integrin have been confirmed; in addition to this the Įvȕ6 binding kinetics for the peptide 
have also been demonstrated. Previously pulished data suggested that A20FMDV2 forms an 
EDTA-resistant complex with Įvȕ6, but only if the peptide-integrin complex is pre-formed 
[25]. It was shown that after 30 min in the presence of an excess of unbiotinylinated 
A20FMDV2, binding could not be reversed from the pre-formed biotinylated A20FMDV2-
Įvȕ6 complex. For comparison in this study, full dissociation profiles over a 24 h time 
course were generated for [
3
H]A20FMDV2, investigating a number of methods to initiate 
radioligand dissociation. These included the sequestering of divalent metal cations (required 
for RGD binding [2]) with EDTA and competition with excess unlabelled ligands (both an 
RGD small molecule binder (SC-68448) and unlabelled A20FMDV2). Over this extended 
timeframe EDTA was able to reverse the binding of [
3
H]A20FMDV2 fully. At 30 min no 
reversal of A20FMDV2 binding to Įvȕ6 was observed by DiCara and co-workers [25] 
whereas in this study ~50% of [
3
H]A20FMDV2 is unbound at this time point. These 
previously published experiments were completed at 4°C. However, in contrast all binding 
experiments in this study were completed at 37°C and therefore an explanation for this could 
be that the slower kinetics at the low temperature conditions resulted in A20FMDV2 
dissociation not being detected at the 30 min time point. When dissociation of 
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[
3
H]A20FMDV2 from Įvȕ6 was initiated by either an RGD small molecule RGD-mimetic 
(SC-68448) or unlabelled A20FMDV2 in this study, only a partial reversal of radioligand 
binding could be achieved up to 24 h. This may provide further evidence for the so-called 
synergy site that has been proposed for the interaction of RGD-containing peptides with a 
number of integrins [26, 27], including Įvȕ6 [28], whereby an interface between the 
secondary structure of the peptide stabilises the RGD site binding. This is supported by 
direct competition at the RGD binding site with SC-68448 not being sufficient to fully 
reverse binding of A20FMDV2 to the Įvȕ6 integrin. Interestingly, the unlabelled 
A20FMDV2 is also unable to compete with the second site that may suggest it is not 
structurally in the correct conformation to achieve this unless first bound to the RGD 
binding site. In agreement with this suggestion, DiCara and co-workers reported that 
A20FMDV2 remains unstructured in solution and only assumes 2D and 3D conformation 
after integrin binding [25]. The full reversal of [
3
H]A20FMDV2 binding observed with 
EDTA may suggest that binding of the peptide to both the RGD site and synergy site 
requires the presence of divalent metal cations. However, it is not clear whether this 
observation is a result of EDTA having a more efficient inhibition of [
3
H]A20FMDV2s 
RGD ligand binding compared with direct competition with an unlabelled RGD-ligand or 
whether binding to the synergy site itself requires the presence of divalent metal cations. In 
contrast to the dissociation studies, the association, saturation and competition binding data 
for [
3
H]A20FMDV2 shows that if the peptide competes with unlabelled Įvȕ6 ligands at the 
same time i.e. is not allowed to form a complex with Įvȕ6, all the radioligand can be 
competed off to NSB levels.  
The regulation of ligand binding to integrins has been shown to be dependent on divalent 
cations due to the presence of allosteric cation binding sites within their protein structure 
[29,30]. Binding of [
3
H]A20FMDV2 to Įvȕ6 also required the presence of divalent cations 
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with Mn
2+
, Mg
2+
 and Ca
2+
 able to support binding. All of these divalent cations were able to 
support maximal binding of the radiolabelled peptide with Įvȕ6 although Mn2+ was able to 
achieve this at ~26- and 35-fold  lower concentrations compared with Mg
2+
 and Ca
2+
 
respectively. The higher potency observed with Mn
2+
 suggested that there was a mixed Įvȕ6 
integrin population in the soluble protein preparation either in the low or high affinity state 
that could be activated with greater efficiency by this divalent cation [30]. 
The Įvȕ3 small molecule RGD-mimetic SC-68448  has been shown in this study to bind to 
Įvȕ6 with moderately high affinity, not previously demonstrated, and has provided a useful 
tool for characterizing the interaction between [
3
H]A20FMDV2 and Įvȕ6. This observation 
suggests that SC-68448 is potentially a pan-Įv integrin RGD-mimetic rather than an Įvȕ3 
selective molecule and may provide a useful tool for probing other members of the RGD 
integrin family. In addition, it has been shown that a truncated version of LAP1 (containing 
the RGD binding motif and flanking amino acids) has a comparable affinity for the Įvȕ6 
integrin compared with the full length LAP1. Although the nH for full length LAP1 was 
steeper (> 1) this is likely a result of being unable to define a complete competition binding 
curve under the constraints on the highest concentration that could be achieved with the full 
length protein (50 nmol/l). Therefore, the truncated form of LAP1 also provides an attractive 
tool for probing the selectivity profile of LAP1 at the other RGD integrins,  as concentrations 
up to high µmol/l could be investigated. This would be extremely useful to understand as it 
could highlight which other TGFȕ activating RGD integrins may be relevant in diseases 
such as IPF and cancer. 
It has been demonstrated that internalization of the integrin occurs following the binding of 
selective peptides (derived from the human foot-and-mouth virus) to Įvȕ6 [15,16]. In this 
study flow cytometry was used to measure the surface expression of Įvȕ6 and its subsequent 
loss post-addition of ligand. Although this technique has not been used routinely for 
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measuring ligand-induced internalization of integrins, it has been used successfully in the G-
protein coupled receptor field investigating agonist and antagonist-induced internalization 
and recycling of the CCR4 receptor [31,32]. A human anti-ȕ6 antibody was used to measure 
the spatial location of the ȕ6 integrin subunit as a marker for Įvȕ6. This was chosen in 
favour of using anti-Įvȕ6 antibodies as these could bind either orthosterically (at the RGD-
site) or allosterically (site distinct from RGD-site) and both would have the potential to 
compete with Įvȕ6 ligands. Orthosteric antibodies would also have the potential to induce 
internalization [33] thus making the measurement of ligand-induced internalization with 
these antibodies not possible. Even though the antibody used for flow cytometry in this 
study was designated as anti-ȕ6, it was still confirmed not to bind and compete with the 
Įvȕ6 integrin (fig. S1). The inferred ligand-induced internalization observed for fLAP1 in 
flow cytometry was abolished in the presence of saponin. Saponin permeabilises the plasma 
cell membrane by forming complexes with cholesterol to generate pores [34] that would 
allow the antibody to access the intracellular pool of Įvȕ6. This not only acted as an 
additional control to confirm fLAP1 was not competing with the anti-ȕ6 antibody but also 
control data showed the total cell Įvȕ6 levels relative to the surface level allowing a 
measurement of intracellular Įvȕ6, with ~64% of integrin present at the cell surface and 
~36% located intracellularly. In addition, it was shown that the Įvȕ6 internalization in the 
NHBE system was being driven by a clathrin-dependent mechanism, that agrees with 
published data where this endocytic mechanism was linked to the Įvȕ6 integrin [35]. 
A20FMDV2 demonstrated a higher potency for Įvȕ6 internalization compared with fLAP1, 
with a comparable difference to that observed with the affinity estimates in radioligand 
binding studies. The endogenous internalization and recycling of the Įvȕ6 integrin has been 
shown to occur very quickly and within 30 minutes [35,36]. However less is known 
regarding ligand-induced Įvȕ6 internalization and the subsequent return of the integrin back 
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to the cell surface.  In this study the rate of internalization was determined for A20FMDV2 
and fLAP1 with both shown to internalise Įvȕ6 very quickly and with comparable t1/2 values 
that were measured within minutes of ligand addition. Furthermore, they both caused a 
comparable level of Įvȕ6 internalization (~80% when normalised to isotype control). The 
more interesting observations in this study were the time of return of Įvȕ6 post-washout of 
ligand.  Both RGD-peptides post-washout had a comparable profile with ~40 or 50 % (for 
fLAP1 and A20FMDV2 respectively) of the total integrin returned to the surface at 48 h still 
internalized at 4 h. The recycling observed in these studies compared with that of 
endogenous turnover of Įvȕ6 is slower, suggesting that the internalised ligand-Įvȕ6 
complex return to the cell surface is being delayed by the RGD-ligand interaction. This is 
comparable to the mechanism by which Į5ȕ1 recycling is dependent on the activation state 
of the integrin [37] as a result of RGD-ligand engagement. 
In summary, this study has confirmed A20FMDV2s high affinity and selectivity for Įvȕ6 
using radioligand binding and has shown it exhibits a complex interaction with the integrin 
post-RGD site binding. The full dissociation of [
3
H]A20FMDV2 from Įvȕ6 observed in the 
presence of EDTA, compared with partial dissociation in the presence of RGD-ligands, 
suggests either the direct A20FMDV2/Įvȕ6 synergy site binding requires the presence of 
metal divalent cations to maintain engagement or it is dependent on the initial RGD-binding 
site interaction. As it is well established that divalent metal cations are required for RGD site 
binding it is likely that the latter mechanism is responsible for maintaining the synergy site 
interface. Therefore, the difference observed between EDTA and direct RGD-ligand 
competition in dissociation studies is potentially due to removal of metal divalent cations 
being able to disengage A20FMDV2 from the RGD site fully, whilst RGD-ligands are 
unable to fully access and dissociate the peptides RGD interaction post-formation of the 
tight A20FMDV2-Įvȕ6 complex.  
 22
In conclusion, the internalization of Įvȕ6 by its endogenous ligand LAP1 has been 
demonstrated for the first time and its profile is comparable to that observed with 
A20FMDV2 whereby a fast internalization rate is followed by a moderatley slow return of 
integrin to the surface. This potentially suggests the RGD-ligand interaction intracellularly 
plays a role in delaying Įvȕ6 recycling to the cell surface acting as a mechanism to control 
subsequent RGD ligand engagement. In addition, this is the first study to characterise the 
RGD-ligand induced internalization of Įvȕ6 in normal human epithelial cells that stands as a 
benchmark for comparison with diseased cells from fibrotic and cancer tissues in future 
studies. 
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FIGURE LEGENDS 
Fig.1. Chemical structures of the RGD ligands used in this study. 
Fig.2. Characterisation of [3H]A20FMDV2 Įvȕ6 integrin binding and RGD integrin 
selectivity. a Association binding kinetics of [3H]A20FMDV2 to the human Įvȕ6 integrin. b 
Dissociation binding kinetics of [
3
H]A20FMDV2 from the human Įvȕ6 integrin. 
Dissociation was initiated by either addition of 10 ȝM SC-68448, 1 ȝM A20FMDV2 or 10 
mmol/l EDTA following a 1 h pre-incubation of [
3
H]A20FMDV2 with Įvȕ6. c Saturation 
binding of [
3
H]A20FMDV2 to the human Įvȕ6 integrin. d [3H]A20FMDV2 binding 
selectivity for the RGD integrins. Radioligand binding was measured by liquid scintillation 
spectroscopy using 0.3 (a, b and c) or 2 (d) nmol/l Įvȕ6 and 2 nmol/l for non-Įvȕ6 RGD 
integrins. For RGD selectivity and saturation binding studies plates were incubated for 4 or 
6 h respectively. Specific binding (a, c and d) was determined from total and non-specific 
binding values measured in the presence of vehicle (1% DMSO) and 10 µmol/l SC-68448 
respectively. Data shown in a, b and c are the mean ± SD of duplicate points and are 
representative of four individual experiments with similar results. Data shown in d are the 
mean ± SEM of four individual experiments carried out in quadruplicate. 
Fig.3. Divalent cation dependency of [3H]A20FMDV2 human Įvȕ6 integrin binding and 
Įvȕ6 competition displacement binding curves. a Specific binding of [3H]A20FMDV2 to 
the human Įvȕ6 integrin in the presence of increasing Ca2+, Mg2+ and Mn2+. b Competition 
displacement binding curves for integrin ligands against [
3
H]A20FMDV2 with the human 
Įvȕ6 integrin. Radioligand binding was measured by liquid scintillation spectroscopy using 
0.3 nmol/l Įvȕ6 and either ~1 (a) or 2 (b) nmol/l [3H]A20FMDV2 following a 4 (a) or 6 (b) 
h incubation. Specific binding was determined from total and non-specific binding values 
measured in the presence of vehicle (1% DMSO) and 10 µmol/l SC-68448 respectively, and 
were used to calculate the % inhibition of radioligand bound to the Įvȕ6 integrin. Data 
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shown are the mean ± SEM of at least four individual experiments carried out in singlicate 
(b) or duplicate (a). 
Fig.4. Ligand-induced Įvȕ6 internalization triggered by fLAP1 in NHBE cells. a Flow 
cytometry histograms showing fLAP1-induced Įvȕ6 internalization. ȕ6 integrin staining was 
determined by flow cytometry where NHBE cells were washed and stained, either with 
(panels 3 and 4) or without (panels 1 and 2) permeabilization (with or without 0.2% w/v 
saponin), with either a PE-conjugated mouse IgG2B isotype control (white histogram), PE-
conjugated mouse monoclonal anti-human integrin ȕ6 (hȕ6-PE) (black histogram) or the 
latter in the presence of 60 nmol/l fLAP1 (grey histogram). Control experiments were 
completed in the presence of 0.1% DMSO with all conditions tested following a 2 h 
incubation. Specific mean fluorescence intensity (MFI) values are shown in each panel in 
bold (geometric mean ± SEM of four individual experiments) and were calculated by 
subtracting the MFI of the negative isotype control from the anti-ȕ6 stained samples. b Flow 
cytometry MFI plots showing fLAP1-induced Įvȕ6 internalization. Significant differences 
between test groups denoted by ** p < 0.01 or * p < 0.05 (ANOVA, Bonferonis post-test). 
Data shown in a are representative of four individual experiments with similar results. Data 
shown in b are the geometric mean ± SEM of four individual experiments carried out in 
duplicate. 
Fig.5. Effect of clathrin-coated pits and lipid rafts disrupting agents on fLAP1-induced 
Įvȕ6 internalization. Inhibition of clathrin or lipid raft mediated endocytosis was 
investigated by pre-incubating NHBE cells with either 2 µg/ml chlorpromazine or 10 µg/ml 
filipin respectively, for 5 min prior to addition of fLAP1 or control (0.1% DMSO) for a 2 h 
incubation. ȕ6 integrin staining was then determined by flow cytometry where NHBE cells 
were washed and stained with either a PE-conjugated mouse IgG2B isotype control (IgG2B-
PE) or PE-conjugated mouse monoclonal anti-human integrin ȕ6 (hȕ6-PE). Significant 
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differences between test groups denoted by ** p < 0.01 (ANOVA, Bonferonis post-test). 
Data shown are the mean ± SEM of three individual experiments carried out in duplicate. ns, 
not significant. 
Fig. 6. RGD ligand-induced internalization and surface repopulation kinetics of the Įvȕ6 
integrin in NHBE cells. a Internalistion concentration response curves were generated by 
incubating compounds at a range of concentrations with NHBE cells for 2 h prior to the 
measurement of the ȕ6 integrin subunit at the cell surface in a flow cytometric assay. b 
Single concentrations of fLAP1 (60 nmol/l) or A20FMDV2 (10 ȝM) were used to induce 
Įvȕ6 internalization at 37ºC. To investigate the kinetics of internalization, plates were 
transferred on to ice at different time points post-compound addition and the ȕ6 integrin 
subunit at the cell surface measured in a flow cytometric assay. To measure the return of the 
Įvȕ6 integrin to the surface post-ligand-induced internalization, NHBE cells were exposed 
to RGD-ligand for 1 h and then washed twice with PBS and additionally incubated at 37ºC 
for various time points up to 48 h. In flow cytometric assays NHBE cells were washed and 
stained with either PE-conjugated mouse IgG2B isotype control (IgG2B-PE) or PE-
conjugated mouse monoclonal anti-human integrin ȕ6 (hȕ6-PE) at the time points indicated. 
Ligand-induced internalization data in a were normalised using the mean fluoresecence 
intensity (MFI) values for the IgG2B-PE and hȕ6-PE in the presence of 0.1% DMSO and 
expressed as % internalised Įvȕ6. For kinetic studies in b data were normalised using the 
MFI values for IgG2B-PE and hȕ6-PE in the presence of vehicle (0.1% DMSO) at each time 
point and expressed as % Įvȕ6 surface expression. Data shown are the mean ± SEM of four 
individual experiments carried out in duplicate. 
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Table 1 The affinity of RGD-ligands for the human Įvȕ6 integrin determined from 
[
3
H]A20FMDV2 saturation and competition binding studies. 
Ligand KD/KI (µmol/l) pKD/pKI nH 
[3H]A20FMDV2 *0.22 ± 0.07 *9.77 ± 0.08 1.20 (0.96, 1.44) 
A20FMDV2 0.24 ± 0.06 9.62 ± 0.05 0.89 (0.67, 1.12) 
SC-68448 12.3 ± 4.21 8.34 ± 0.28 1.00 (0.87, 1.14) 
tLAP1 0.50 ± 0.12 8.54 ± 0.12 1.01 (0.81, 1.22) 
fLAP1 1.05 ± 0.16 9.00 ± 0.08 1.83 (0.56, 3.11) 
Cilengitide <122 <6.92 N/A 
 
Data shown are mean values ± S.E.M. for at least four separate determinations. pKD, 
negative log10 of KD; pKI, negative log10 of KI; nH, Hill slope; *denotes KD/pKD; N/A, not 
applicable. 
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SUPPLEMENTARY DATA 
SUPPLEMENTARY MATERIALS AND METHODS 
Įvȕ6 Mediated Cell Adhesion 
The myelogenous leukemia K562 cell line (S1) stably expressing the Įvȕ6 integrin (K562-
Įvȕ6) was generated by the Biological Sciences Department at GSK Medicines Research 
Centre (Stevenage, UK) using previously described methods (S2). K562-Įvȕ6 cells were 
cultured as a suspension in T175 tissue culture flasks using aseptic techniques in equal 
volumes of Roswell Park Memorial Institute (RPMI) 1640 and Dulbecco's Modified Eagles 
Medium (DMEM) containing 10 % heat inactivated fetal calf serum (FCS), 2 mmol/l 
glutamine and 1 mg/ml geneticin in 95 %:5 % air:CO2 at 37ºC. Glutathione S-transferase 
fusion LAP-TGFȕ-1 (GST-LAP1) protein (generated as previously described (S2), 
corresponding to the RGD integrin-binding domain of LAP1 (amino acids 242-252  
GRRGDLATIHG), was coated (100 µl/well) onto 96-well MaxiSorp® flat-bottom plates 
(Thermo Fisher Scientific, MA, USA) at a concentration of 100 µg/ml and incubated for 2 h 
at 37ºC. Plates were then washed twice with 200 µl/well PBS after which blocked with 3 % 
w/v BSA in PBS (100 µl/well) for 1 h. Plates were then washed twice with 200 µl/well PBS 
and 25 µl/well of cell adhesion assay buffer (Hanks balanced salt solution (HBSS) 
containing 25 mM HEPES) containing 8 mM MgCl2 was added. Test antibodies (mouse 
IgG2A isotype control (IgG2A), mouse IgG2B isotype control (flow unconjugated IgG2B) 
(both generated by BioPharm Research and Development department at GSK Medicines 
Research Centre (Stevenage, UK)), mouse monoclonal anti-human integrin beta-6 (flow 
unconjugated anti-ȕ6) (R&D Systems, Minneapolis, MN, USA) and RGD-mimetic blocking 
monoclonal anti-human integrin Įvȕ6 clone 10D5 (10D5 anti-Įvȕ6) (Merck Millipore, 
Billerica, MA, USA)) were made up in cell adhesion assay buffer (0.4 % DMSO to give a 
final DMSO concentration of 0.1 %) and added to plates (25 µl/well). K562-Įvȕ6 cells were 
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re-suspended to 0.25 or 3 x 10
6
 cells/ml respectively, and 2',7'-bis-(2-carboxyethyl)-5-(and-
6)-carboxyfluorescein, acetoxymethyl ester (BCECF-AM) added to give a final 
concentration of 5 µmol/l prior to a 10 min incubation at 37ºC. K562-Įvȕ6 cells (0.15 x 106 
cells/well with 50 µl/well) were then added to plates (giving a final MgCl2 concentration of 
2 mM) prior to a 30 min incubation at 37ºC. Plates were then washed twice with 200 µl/well 
PBS and 50 µl/well 0.5 % Triton X-100 detection solution added. Following a 5 min 
incubation at ambient temperature (20-22ºC) fluorescence (relative light units) was 
measured (excitation wavelength 485 nm and emission wavelength 535 nm) using an 
EnVision® multilabel plate reader (PerkinElmer LAS UK Ltd., Beaconsfield, UK). In order 
to average data between separate experimental determinations in the K562-Įvȕ6 assay 
format, data were normalised within experiments using a positive (10 mM EDTA) and 
negative control (0.1 % DMSO).  
SUPPLEMENTARY FIGURE LEGEND 
Fig.S1. ȕ6 flow cytometry antibodies do not inhibit Įvȕ6 cell adhesion to GST-LAP1. The 
effect of blocking and unconjugated flow cytometry ȕ6 antibodies (including isotype 
controls) on Įvȕ6 cell adhesion was measured by incubating antibodies at 100 µg/ml with 
K562 cells recombinantly expressing the Įvȕ6 integrin in plates coated with GST-LAP1. 
Plates were incubated for 30 min prior to removal of non-adhering cell populations and the 
remaining adhered cells were then quantified by fluorescence using BCECF-AM. Total and 
non-specific binding values were measured in the presence of vehicle (1 % DMSO) and 10 
mM EDTA respectively, and were used to calculate the % inhibition of cell adhesion. Data 
shown are the mean ± SEM of at least four individual experiments carried out in singlicate. 
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A20FDMV2 (amino acid sequence NAVPNLRGDLQVLAQKVART)
[3H]A20FDMV2 (amino acid sequence NAVPNLRGDLQVLAQKVART)
LSTCKTIDMELVKRKRIEAIRGQILSKLRLASPPSQGEVPPGPLPEAVLALYNSTRDRVAGESA
EPEPEPEADYYAKEVTRVLMVETHNEIYDKFKQSTHSIYMFFNTSELREAVPEPVLLSRAELR
LLRLKLKVEQHVELYQKYSNNSWRYLSNRLLAPSDSPEWLSFDVTGVVRQWLSRGGEIEGF
RLSAHCSCDSRDNTLQVDINGFTTGRRGDLATIHGMNRPFLLLMATPLERAQHLQSSRHRR
Full length TGFȕ1 latency associated peptide (fLAP1) amino acid sequence (RGD integrin binding sequence in bold)
Cilengitide
Truncated TGFȕ1 latency associated peptide (tLAP1) (amino acid sequence GRRGDLATIHG)
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Fig. 1
0.0 0.5 1.0 1.5 2.0
0
1000
2000
3000
4000
Sp
e
c
ifi
c 
[3 H
]A
20
FM
D
V2
 
bo
u
n
d 
(D
PM
)
[[3H]A20FMDV2] nmol/l
c
0 4 8 12 16 20 24
0
20
40
60
80
100
120
Time (h)
%
 [3
H
]A
20
FM
D
V2
 
bo
u
n
d
10 Pmol/l SC-68448
1 Pmol/l A20FMDV2
10 mmol/l EDTA
b
0 20 40 60 80 100 120
0
1000
2000
3000
4000
Sp
e
c
ifi
c
 
[3 H
]A
20
FM
D
V2
 
bo
un
d 
(D
PM
)
Time (min)
0.3 nmol/l
1.6 nmol/l
[3H]A20FMDV2
a
6EvD
1EvD
3EvD
5EvD
8EvD
1E5D
1E8D
3E
IIbD
0.0
0.5
1.0
1.5
2.0
2.5
Sp
e
c
ifi
c 
[3 H
]A
20
FM
D
V2
 
bo
un
d 
(fm
o
l/n
g)
RGD Integrind
Fig. 2
-13 -12 -11 -10 -9 -8 -7 -6 -5 -4
-20
0
20
40
60
80
100
120
SC-68448
A20FMDV2
tLAP1
fLAP1
Cilengitide
b
Log [Compound] mol/l%
 
in
hi
bi
tio
n
 o
f [
3 H
]A
20
FM
D
V2
 
bi
n
di
n
g
-8 -7 -6 -5 -4 -3 -2 -1
0.0
0.5
1.0
1.5
2.0
Mg2+
Mn2+
Ca2+
a
Log [divalent cation] mol/lSp
e
c
ifi
c 
[3 H
]A
20
FM
D
V2
 
bo
un
d 
(fm
o
l/n
g)
Fig. 3
g
Control fLAP1
17 163 7 4481 2
Co
un
ts
Co
un
ts
M
em
br
an
e 
St
ai
ni
ng , ,
u
n
ts
u
n
ts
M
ll 
St
ai
ni
ng
27,197 25,52043
Co Co
To
ta
l C
el
MFI
30000
35000 IgG2B-PE
hE6-PE
**
**
e
n
s
ity
a
5000
10000
15000
20000
25000 hE6-PE + 60 nmol/l fLAP1** *
n
 
flu
o
re
s
c
e
n
c
e
 in
te
0 % w/v saponin 0.2 % w/v saponin
0M
ea
n
b
Fig. 4
IgG
2B
-
PE
-
PE
6Eh
1
-
PE
 + 
60
 nm
ol/
l fL
AP
6Eh
0
5000
10000
15000
20000
25000 Control
2 Pg/ml chlorpromazine
10 Pg/ml f ilipin
**
ns
M
e
a
n
 
flu
o
re
s
c
e
n
c
e
 in
te
n
s
ity
Fig. 5
-12 -11 -10 -9 -8 -7 -6 -5
0
25
50
75
100
fLAP1
A20FMDV2
a
Log [Compound] mol/l
%
 
in
te
rn
a
lis
e
d
D v
E 6
0.0 0.5 1.0
0
20
40
60
80
100
10 20 30 40 50
60 nmol/l fLAP1
1 Pmol/l A20FMDV2
Washout
b
Time (h)
%
D v
E 6
 s
u
rf
a
c
e
 e
x
pr
e
s
s
io
n
Fig. 6
6EvD
10
D5
 
an
ti- Ig
G2
A 6E
Flo
w
 
un
co
nju
ga
ted
 
an
ti-
Flo
w
 
un
co
nju
ga
ted
 Ig
G2
B
0
20
40
60
80
100
%
 
in
hi
bi
tio
n
 
o
f c
e
ll 
a
dh
es
io
n
Fig. S1
